1. Home
  2. BA vs GILD Comparison

BA vs GILD Comparison

Compare BA & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boeing Company (The)

BA

Boeing Company (The)

HOLD

Current Price

$235.88

Market Cap

183.0B

Sector

Industrials

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$149.39

Market Cap

170.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BA
GILD
Founded
1916
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.0B
170.9B
IPO Year
N/A
1992

Fundamental Metrics

Financial Performance
Metric
BA
GILD
Price
$235.88
$149.39
Analyst Decision
Strong Buy
Buy
Analyst Count
19
21
Target Price
$252.00
$130.10
AVG Volume (30 Days)
8.7M
7.9M
Earning Date
01-27-2026
02-10-2026
Dividend Yield
N/A
2.16%
EPS Growth
N/A
6514.05
EPS
2.48
6.42
Revenue
$89,463,000,000.00
$29,087,000,000.00
Revenue This Year
$11.31
$3.66
Revenue Next Year
$14.90
$3.32
P/E Ratio
$95.14
$22.77
Revenue Growth
34.50
2.79
52 Week Low
$128.88
$93.37
52 Week High
$254.35
$146.73

Technical Indicators

Market Signals
Indicator
BA
GILD
Relative Strength Index (RSI) 53.52 80.17
Support Level $228.96 $138.23
Resistance Level $238.85 $141.71
Average True Range (ATR) 7.05 3.96
MACD -2.71 1.56
Stochastic Oscillator 29.26 95.56

Price Performance

Historical Comparison
BA
GILD

About BA Boeing Company (The)

Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: